Since inflammatory processes contribute to PD pathogenesis [71] and the positive effects of GPR55 activation have already been shown, reducing cytokine and chemokine levels via GPR55 activation might be a promising approach in novel PD therapies. The gene discussed is GPR55; the disease is Parkinson disease.